X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).
Lead Product(s): BV500
Therapeutic Area: Infections and Infectious Diseases Product Name: BV500
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: CF AMR Syndicate
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding June 04, 2024
Details:
The proceeds will enable the clinical development of BioVersys’ portfolio which includes BV100 (rifabutin), a potential breakthrough hospital antibiotic with a new mode of action targeting Acinetobacter baumannii, the most drug-resistant bacterial pathogen.
Lead Product(s): Rifabutin
Therapeutic Area: Infections and Infectious Diseases Product Name: BV100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: $49.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 07, 2024
Details:
The collaboration with the GSK to accelerate the clinical development of BVL-GSK098 (alpibectir) for the treatment of tuberculosis.
Lead Product(s): Alpibectir,Ethionamide
Therapeutic Area: Infections and Infectious Diseases Product Name: BVL-GSK098
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 07, 2024
Details:
BioVersys' lead candidate, BV100 (rifabutin), is being developed for lung and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB).
Lead Product(s): Rifabutin
Therapeutic Area: Infections and Infectious Diseases Product Name: BV100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AMR Action Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 05, 2023
Details:
BV100 is a much-needed injectable formulation of rifabutin to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii in patients with ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia and bloodstream infections.
Lead Product(s): Rifabutin
Therapeutic Area: Infections and Infectious Diseases Product Name: BV100
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Curetis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 25, 2022
Details:
BioVersys has developed a proprietary human IV formulation of BV100 for the CRAB hospital market and elucidated the unique mode of action that accounts for its tremendous potency and coverage of clinical CRAB isolates.
Lead Product(s): Rifabutin
Therapeutic Area: Infections and Infectious Diseases Product Name: BV100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
